PE20010632A1 - Derivados de ter-butil-(7-metil-imidazol[1,2-a]piridin-3-il)-amina, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen - Google Patents

Derivados de ter-butil-(7-metil-imidazol[1,2-a]piridin-3-il)-amina, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen

Info

Publication number
PE20010632A1
PE20010632A1 PE2000001063A PE0010632000A PE20010632A1 PE 20010632 A1 PE20010632 A1 PE 20010632A1 PE 2000001063 A PE2000001063 A PE 2000001063A PE 0010632000 A PE0010632000 A PE 0010632000A PE 20010632 A1 PE20010632 A1 PE 20010632A1
Authority
PE
Peru
Prior art keywords
pyridin
methyl
imidazol
procedure
preparation
Prior art date
Application number
PE2000001063A
Other languages
English (en)
Inventor
Johannes Schneider
Bernd Sundermann
Hagen-Heinrich Hennies
Matthias Gerlach
Corinna Maul
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20010632A1 publication Critical patent/PE20010632A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A DERIVADOS DE TERBUTIL-(7-METIL-IMIDAZOL[1,2-a]PIRIDIN-3-IL)-AMINA DE FORMULA I, DONDE R1 ES H, ALCANILO C1-C4; R2 ES ALQUILO C1-C8, CICLOALQUILO C3-C8, HETEROCICLO, ARILO, HETEROARILO, ENTRE OTROS; EXCEPTO COMPUESTOS CUANDO R1 ES METILO; R2 ES FENILO. SON COMPUESTOS PREFERIDOS TERBUTIL-(7-METIL-2-PIRIDIN-3-IL-IMIDAZOL[1,2-a]PIRIDIN-3-IL)AMINA, TERBUTIL-[2-(2,3-DIMETOXI-FENIL)-5,7-DIMETIL-IMIDAZO[1,2-a]PIRIDIN-3-IL]AMINA, 3-(3-TERBUTILAMINO-5,7-DIMETIL-IMIDAZO[1,2-a]PIRIDIN-2-IL)-FENOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN INHIBIDOR DE MONOXIDO DE NITROGENO SINTASA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE SHOCK SEPTICO, ESCLEROSIS MULTIPLE, PARKINSON, ALZHEIMER, HUNTINGTON, INFLAMACIONES, DOLORES INFLAMATORIOS, ISQUEMIA CEREBRAL, DIABETES, MENINGITIS, ARTERIOSCLEROSIS, CURACION DE HERIDAS
PE2000001063A 1999-10-08 2000-10-06 Derivados de ter-butil-(7-metil-imidazol[1,2-a]piridin-3-il)-amina, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen PE20010632A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19948434A DE19948434A1 (de) 1999-10-08 1999-10-08 Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine

Publications (1)

Publication Number Publication Date
PE20010632A1 true PE20010632A1 (es) 2001-07-07

Family

ID=7924888

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2000001063A PE20010632A1 (es) 1999-10-08 2000-10-06 Derivados de ter-butil-(7-metil-imidazol[1,2-a]piridin-3-il)-amina, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen
PE2000001062A PE20010706A1 (es) 1999-10-08 2000-10-06 Biblioteca de sustancias que contiene imidazo-5-il-aminas biciclicas y/o imidazo-3-il-aminas biciclicas, procedimiento para la preparacion de esta biblioteca de sustancias, y uso de sustancias de esta biblioteca para la preparacion de medicamentos pa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2000001062A PE20010706A1 (es) 1999-10-08 2000-10-06 Biblioteca de sustancias que contiene imidazo-5-il-aminas biciclicas y/o imidazo-3-il-aminas biciclicas, procedimiento para la preparacion de esta biblioteca de sustancias, y uso de sustancias de esta biblioteca para la preparacion de medicamentos pa

Country Status (28)

Country Link
US (1) US6703404B2 (es)
EP (1) EP1218378B1 (es)
JP (1) JP2003511450A (es)
KR (1) KR100793619B1 (es)
CN (1) CN1208336C (es)
AR (2) AR025959A1 (es)
AT (1) ATE238304T1 (es)
AU (2) AU7419900A (es)
BR (1) BR0014827A (es)
CA (1) CA2386804A1 (es)
CO (2) CO5210861A1 (es)
CZ (1) CZ20021241A3 (es)
DE (2) DE19948434A1 (es)
DK (1) DK1218378T3 (es)
ES (1) ES2198355T3 (es)
HK (1) HK1047749B (es)
HU (1) HUP0203545A3 (es)
IL (3) IL148997A0 (es)
MX (1) MXPA02003546A (es)
NO (1) NO20021564L (es)
NZ (1) NZ518438A (es)
PE (2) PE20010632A1 (es)
PL (1) PL355109A1 (es)
PT (1) PT1218378E (es)
RU (1) RU2002110281A (es)
SK (1) SK4622002A3 (es)
WO (2) WO2001027119A2 (es)
ZA (2) ZA200203579B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
WO2000016763A2 (en) 1998-09-21 2000-03-30 University Of Florida Research Foundation, Inc. Antimalarial agents
AU2001251444A1 (en) 2000-04-10 2001-10-23 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
DE10043845A1 (de) * 2000-09-06 2002-03-14 Gruenenthal Gmbh Verfahren zur Messung der Aktivität der NO-Synthase
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
WO2002048146A2 (de) * 2000-12-13 2002-06-20 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
DE10117184A1 (de) * 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10132726A1 (de) 2001-07-05 2003-02-27 Gruenenthal Gmbh Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel
EP1483247B1 (en) 2002-03-13 2009-06-24 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
US6919340B2 (en) 2002-04-19 2005-07-19 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US20050197435A1 (en) * 2002-06-14 2005-09-08 Dotson Darin L. Polymer additive compositions for bimolecular nucleation in thermoplastics
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
DE10246890A1 (de) 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
DE102004044884A1 (de) * 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
DE102005016547A1 (de) * 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
JP2008540674A (ja) 2005-05-20 2008-11-20 アレイ バイオファーマ、インコーポレイテッド Raf阻害化合物およびその使用方法
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006278396A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
PL1973545T3 (pl) 2005-12-23 2013-05-31 Ariad Pharma Inc Bicykliczne Związki Heteroarylowe
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
NZ571566A (en) 2006-03-17 2011-07-29 Ambit Biosciences Corp Imidazolothiazole compounds for the treatment of disease
WO2008115433A1 (en) 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
BRPI0816904B8 (pt) 2007-09-19 2021-12-07 Ambit Biosciences Corp Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
BRPI0911659B8 (pt) * 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
EP2334675B1 (en) * 2008-09-16 2014-03-26 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
VN28228A1 (en) 2008-12-08 2011-12-26 Gilead Connecticut Inc Imidazopyrazine Syk inhibitors
WO2010068258A1 (en) 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Imidazopyrazine syk inhibitors
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
AU2012352025B2 (en) 2011-12-16 2018-01-18 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
EA201491967A1 (ru) 2012-04-26 2015-03-31 Бристол-Майерс Сквибб Компани Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
EP3243826B1 (en) 2012-04-26 2019-10-30 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
BR112014026651A8 (pt) 2012-04-26 2018-01-16 Bristol Myers Squibb Co derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária
CA2884767A1 (en) * 2012-11-14 2014-05-22 Stephan Bachmann Imidazopyridine derivatives
SG11201600378SA (en) 2013-07-30 2016-02-26 Gilead Connecticut Inc Formulation of syk inhibitors
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Syk 억제제의 다형체
WO2015077655A1 (en) 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
CN105764516A (zh) 2013-12-04 2016-07-13 吉利德科学公司 治疗癌症的方法
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CR20200362A (es) 2014-02-13 2020-10-26 Incyte Corp CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
HUE046273T2 (hu) 2014-02-13 2020-02-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
KR20170029580A (ko) 2014-07-14 2017-03-15 길리애드 사이언시즈, 인코포레이티드 암을 치료하기 위한 조합물
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
JP2018515475A (ja) 2015-04-27 2018-06-14 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. 代謝的にプログラムされた金属キレーターおよびその使用
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Lsd1阻害剤の塩
ES2963148T3 (es) 2016-04-22 2024-03-25 Incyte Corp Formulaciones de un inhibidor de LSD1
WO2019014514A1 (en) * 2017-07-14 2019-01-17 University Of Massachusetts HETEROCYCLIC COMPOUNDS AND USES THEREOF
KR20220070056A (ko) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
JP2020536853A (ja) * 2017-10-04 2020-12-17 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 転写因子sall4の小分子阻害およびその使用
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
EP0266890A1 (en) * 1986-10-07 1988-05-11 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them
FR2638161B1 (fr) * 1988-10-24 1991-01-11 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH08333258A (ja) * 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1998006724A1 (fr) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents

Also Published As

Publication number Publication date
AR025959A1 (es) 2002-12-26
ATE238304T1 (de) 2003-05-15
CN1208336C (zh) 2005-06-29
CN1407983A (zh) 2003-04-02
BR0014827A (pt) 2003-07-08
AR025960A1 (es) 2002-12-26
NZ518438A (en) 2004-08-27
CO5210861A1 (es) 2002-10-30
AU780526B2 (en) 2005-03-24
ZA200203579B (en) 2003-10-29
ZA200203581B (en) 2004-02-25
PT1218378E (pt) 2003-09-30
NO20021564D0 (no) 2002-04-03
HUP0203545A3 (en) 2004-07-28
EP1218378A2 (de) 2002-07-03
IL148997A0 (en) 2002-11-10
AU7915300A (en) 2001-04-23
KR100793619B1 (ko) 2008-01-11
JP2003511450A (ja) 2003-03-25
IL148999A (en) 2007-03-08
WO2001027109A2 (de) 2001-04-19
US6703404B2 (en) 2004-03-09
IL148999A0 (en) 2002-11-10
SK4622002A3 (en) 2002-09-10
CO5251429A1 (es) 2003-02-28
CZ20021241A3 (cs) 2002-08-14
ES2198355T3 (es) 2004-02-01
WO2001027119A3 (de) 2001-10-11
AU7419900A (en) 2001-04-23
WO2001027109A3 (de) 2001-09-20
HK1047749A1 (en) 2003-03-07
RU2002110281A (ru) 2003-12-20
HUP0203545A2 (hu) 2003-02-28
MXPA02003546A (es) 2002-09-18
HK1047749B (zh) 2003-08-22
US20030022914A1 (en) 2003-01-30
CA2386804A1 (en) 2001-04-19
PL355109A1 (en) 2004-04-05
NO20021564L (no) 2002-06-04
EP1218378B1 (de) 2003-04-23
DK1218378T3 (da) 2003-07-21
KR20020069003A (ko) 2002-08-28
DE19948434A1 (de) 2001-06-07
WO2001027119A2 (de) 2001-04-19
PE20010706A1 (es) 2001-08-13
DE50001911D1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
PE20010632A1 (es) Derivados de ter-butil-(7-metil-imidazol[1,2-a]piridin-3-il)-amina, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen
RU2331643C2 (ru) Пиразолопиримидины и средство, обладающее фунгицидной и бактерицидной активностью для борьбы с вредными организмами, на их основе
ATE556058T1 (de) 1-(2h)-isochinolonderivat
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
TW200710086A (en) Diaryl-substituted hetero 5-membered ring derivatives
RS52061B (en) PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
TW200612920A (en) Novel imidazolidine derivatives
MEP9208A (en) Quinoline derivatives and their use as mycobacterial inhibitors
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
RS53627B1 (en) N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
ATE512955T1 (de) Stickstoffhaltige heterozyklische derivate und medikamente die diese enthalten
BRPI0513777A (pt) composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
PE20100737A1 (es) Nuevos compuestos
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
RU2007122406A (ru) Производные тетралина и индана и их применения в качестве антагонистов 5-нт
ID30498A (id) Senyawa-senyawa turunan amina
PE20010638A1 (es) Imidazo-5-il-aminas biciclicas, medicamentos que las contienen, su uso para la preparacion de medicamentos y procedimiento para su preparacion
CA2619897A1 (fr) Nouveaux derives tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR970703324A (ko) 신규한 피리미딘 유도체(novel pyrimidine derivative)
PE20020906A1 (es) Inhibidores de peptido-deformilasa
KR880002829A (ko) 디하이드로피리딘 항알러지제 및 소염제
DE69925472D1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed